Translating Science into Survival: Report on the Fourth International Cancer Immunotherapy Conference
- PMID: 30602506
- DOI: 10.1158/2326-6066.CIR-18-0866
Translating Science into Survival: Report on the Fourth International Cancer Immunotherapy Conference
Abstract
On September 30 to October 3, 2018, in New York City, the Fourth International Cancer Immunotherapy Conference (CICON) was hosted jointly by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology, and the American Association for Cancer Research (AACR). For the fourth straight year, more than 1,400 people attended the 4-day event, which covered the latest advances in cancer immunology and immunotherapy. This year's meeting also coincided with the announcement that the 2018 Nobel Prize in Medicine or Physiology would be awarded to one of CICON's attendees, James P. Allison.
©2019 American Association for Cancer Research.
Similar articles
-
Translating Science into Survival: Report on the Third International Cancer Immunotherapy Conference.Cancer Immunol Res. 2018 Jan;6(1):10-13. doi: 10.1158/2326-6066.CIR-17-0656. Cancer Immunol Res. 2018. PMID: 29298782
-
Translating Science into Survival: Report on the Fifth International Cancer Immunotherapy Conference.Cancer Immunol Res. 2020 Jan;8(1):3-6. doi: 10.1158/2326-6066.CIR-19-0888. Cancer Immunol Res. 2020. PMID: 31909729
-
Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference.Cancer Immunol Res. 2016 Jan;4(1):3-11. doi: 10.1158/2326-6066.cir-15-0279. Cancer Immunol Res. 2016. PMID: 27119139
-
Development of immune checkpoint therapy for cancer.J Exp Med. 2019 Jun 3;216(6):1244-1254. doi: 10.1084/jem.20182395. Epub 2019 May 8. J Exp Med. 2019. PMID: 31068379 Free PMC article. Review.
-
Putting the Immunologic Brakes on Cancer.Cell. 2018 Nov 29;175(6):1452-1454. doi: 10.1016/j.cell.2018.11.006. Cell. 2018. PMID: 30500529 Review.
Cited by
-
SILAC-based quantitative proteomics and microscopy analysis of cancer cells treated with the N-glycolyl GM3-specific anti-tumor antibody 14F7.Front Immunol. 2022 Nov 9;13:994790. doi: 10.3389/fimmu.2022.994790. eCollection 2022. Front Immunol. 2022. PMID: 36439103 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources